Sangamo selects winning bids in Chapter 11 asset auction for USD 163.55 million cash at close
SGMO•Winning bids in Chapter 11 asset auction
Sangamo Therapeutics selected winning bids in a court-supervised Chapter 11 asset auction totaling USD 163.55 million cash at closing.
- PTC Therapeutics set to buy the Fabry disease program ST-920 for USD 111 million, with up to USD 100 million tied to FDA approvals.
- Eli Lilly to acquire capsid delivery, zinc finger, MINT platforms, and prion program ST-506 for USD 50 million in cash.
- Separate sales of tools and equipment expected to add USD 2.55 million in cash proceeds at closing.
- Transactions await U.S. Bankruptcy Court sign-off; Lilly closing targeted around Sept. 4, 2026.
